Our Experience

Biopharmaceuticals, Gene Therapies, and Biologic Therapies

Representative engagements have addressed:

• Adenovirus-based gene therapy interferon delivery system for the indications of primary glioma and metastatic colorectal cancer
• Adenovirus-based gene therapy system for the indication of cystic fibrosis
• Adenovirus-based gene therapy system for the indication of familial hypercholesterolemia
• Adenovirus-based gene therapy system for the indication of mesothelioma
• Antibody-based C5-blocking immunomodulator for the indications of post-ischemic reperfusion injury and rheumatoid arthritis
• Antibody-based CD20-targeting anticancer therapy for the indications of non-Hodgkin's lymphoma and chronic lymphocytic lymphoma
• Antibody-based CD20-targeting radioisotope anticancer therapy for the indications of low grade and transformed refractory B-cell lymphomas
• Antibody-based complement ligand therapy for the indications of allergic rhinitis, systemic sclerosis, and poliomyelitis
• Antibody-based immunomodulator for the prophylaxis of primary cytomegalovirus infection during pregnancy
• Antibody-based immunomodulator vaccine for the indications of neonatal and pediatric respiratory syncitial virus
• Antibody-based membrane-targeted immunomodulator for the indication of advanced prostate cancer
• Autologous antigen-presenting dendritic cell therapy for the indication of advanced prostate cancer
• Carbohydrate-based infection-reducing biopharmaceutical for the indication of high-risk GI surgery prophylaxis
• Complement-inhibiting recombinant membrane protein for the indications of stroke and traumatic brain injury
• Embryonic brain cell xenograft therapy for the indication of Parkinson’s disease
• Factor D-inhibiting immunomodulator for the indication of acute myocardial infarction and stroke
• Fibrolast-modulating scar-reducing recombinant growth factor for use during peripheral and spinal neurosurgical procedures
• High-throughput polymer bead-based manufacturing system for protein-based biopharmaceuticals
• Hyaluronic acid-based adhesion-reducing biopharmaceutical formulation for use during abdominal and obstetric surgical procedures
• Hyaluronic acid-based procedure-enhancing biopharmaceutical formulation for use during anterior segment ophthalmic surgery procedures
• Islet cell-based xenograft biologic therapy for adult and pediatric Type I diabetes
• Nephron-sparing recombinant growth factor for the indication of chronic renal insufficiency
• Neural-regenerating fibroblast growth factor for the indication of acute ischemic stroke
• PEGylated and glycosylated interferon variants for the indication of chronic persistent hepatitis C
• PEGylated hematopoetic growth factor for the treatment of neutropenia
• Protein kinase-inhibiting cytoprotective immunomodulator for use during cancer chemotherapy
• Protein-based hemostasis-enhancing biopharmaceutical for use during high blood loss surgical procedures and trauma
• Recombinant alpha interferon for the indication of hepatitis C
• Recombinant alpha interferon variant for the indication of malignant melanoma
• Recombinant antithrombin immunomodulator for mutiple indications of viral disease
• Recombinant beta amyloid-inhibiting ketinin for the prophylaxis and treatment of Alzheimer’s dementia
• Recombinant complement-inhibiting immunomodulator for multiple indications of autoimmune disease
• Recombinant fusion protein vaccine for the indication of pediatric respiratory syncitial virus
• Recombinant glial growth factor for the indications of metabolic, toxic, and traumatic peripheral neuropathies
• Recombinant hematopoetic growth factor for the treatment of neutropenia
• Recombinant human growth hormone injectable reformulation for the indications of pediatric and adult growth hormone deficiency
• Recombinant immunomodulator for the indication of acute pancreatitis
• Recombinant immunomodulator for the indication of inflammatory bowel disease
• Recombinant immunomodulator for the indication of systemic lupus erythematosis
• Recombinant immunomodulator for the indication of uveitis
• Recombinant immunomodulator for the indications of neonatal cerebral ischemia secondary to uteroplacental insufficiency, dystocia, and birth trauma
• Recombinant interferon for the indication of inflammatory bowel disease maintenance and suppression therapy
• Recombinant interferon variant for the indication of multiple sclerosis
• Recombinant next-generation beta interferon for the indications of hematologic cancers and malignant melanoma
• Recombinant next-generation colony stimulating factor for the indications for myelosuppression, bone marrow transplant, acute myelogenous leukemia, and HIV
• Recombinant PDGF-associated tyrosine kinase inhibitor for the indications of chronic myelogenous and acute lymphocytic leukemia
• Recombinant platelet activation inhibitor for the indications of cardiogenic shock and sepsis
• Recombinant renal-protecting and regenerating growth factor for the indication of chronic renal failure
• Recombinant renal-regenerating growth factor for the indications of acute tubular necrosis and acute renal failure
• Recombinant second-generation glucocerebrosidase for the indication of clinically-significant Gaucher’s disease
• Recombinant second-generation thrombolytic enzyme for the indications of stroke, coronary artery thrombosis, and arterial thrombosis
• Recombinant T-cell activity-modulating fusion protein for the indication of psoriasis
• Recombinant thrombolytic enzyme for the indications of pulmonary embolisms and coronary artery thrombosis